Nomura Holdings Inc. Takes Position in Solventum Co. (NYSE:SOLV)

Nomura Holdings Inc. purchased a new position in shares of Solventum Co. (NYSE:SOLV - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 143,442 shares of the company's stock, valued at approximately $9,476,000. Nomura Holdings Inc. owned about 0.08% of Solventum as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Clarity Asset Management Inc. bought a new position in shares of Solventum in the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC bought a new stake in shares of Solventum in the 4th quarter valued at approximately $26,000. Crews Bank & Trust bought a new position in shares of Solventum during the 4th quarter worth approximately $32,000. Colonial Trust Co SC boosted its stake in Solventum by 240.7% in the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after buying an additional 361 shares in the last quarter. Finally, Synergy Asset Management LLC bought a new stake in Solventum in the fourth quarter valued at $35,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SOLV shares. Morgan Stanley lifted their price target on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. Bank of America upped their target price on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, February 26th. Mizuho lifted their target price on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Wells Fargo & Company raised their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group raised their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $80.29.

Solventum Trading Down 1.3%

Shares of SOLV stock traded down $0.97 during mid-day trading on Tuesday, reaching $74.80. 205,577 shares of the stock traded hands, compared to its average volume of 1,244,134. The company has a market cap of $12.94 billion and a price-to-earnings ratio of 34.58. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock's fifty day simple moving average is $69.83 and its two-hundred day simple moving average is $71.28. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.19 by $0.15. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. During the same quarter in the prior year, the business earned $2.08 earnings per share. The firm's quarterly revenue was up 2.7% on a year-over-year basis. On average, research analysts anticipate that Solventum Co. will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.